Wild West: Exome Sequencing in the Clinic
Avni B. Santani, Ph.D., Assistant Professor, Clinical Pathology, University of Pennsylvania School of Medicine; Scientific Director, Molecular Genetics Laboratory, The Children’s Hospital of Philadelphia
Avni Santani of CHOP speaks to CHI on Tuesday August 1st, 2018. Dr. Santani will be speaking during the Clinical NGS Assays: Applications and Interpretation meeting at the Next Generation Diangostics SummitAugust 15-18, in Washington DC.
The Role of Molecular Diagnostics in Antibiotics Stewardships Programs
Elena Grigorenko, Vice President, Research and Development, Diatherix, Eurofins Clinical Diagnostics, LLC
Dr. Elena Grigorenko of Diatherix, speaks to CHI on Wed. July 19, 2017. Dr. Grigorenko will be speaking during the Molecular Diagnostics for Infectious Disease Conference August 16-17, 2017 at the Grand Hyatt Washington in Washington, DC
Point-of-Care Devices in Liquid Biopsy
Andrew H. Ko, M.D., Professor, Clinical Medicine, Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
Andrew Ko from UCSF recently spoke with CHI about his collaboration with Two Pore Guys, and the innovations they are implementing using point-of-care devices in liquid biopsy. He will be speaking at the Next-Generation Dx Summit in the Enabling
Point-of-Care Diagnostics conference on August 15. Dr. Ko is working with Two Pore Guys advancing technology to enable cancer patients to monitor their progress from home.
Point-of-Care Devices in Immunotherapy and Beyond
M. Allen Northrup, Ph.D., FRSC, CEO, MIODx
Dr. Allen Northrup from MIODx recently spoke with CHI about the future applications of point-of-care in treating cancer. He will be speaking at the Next-Generation Dx Summit in the Enabling Point-of-Care Diagnostics conference on August 15. He
is working on developments to predict and monitor patients’ responses to immunotherapy.
The Microbiome’s Diagnostic Potential in Infectious Disease Point-of-Care Assays
Georgios Kitsios, M.D., Ph.D., Instructor of Medicine; Post-Doctoral Scholar, Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center
Georgios Kitsios of the University of Pittsburgh Medical Center spoke to CHI to discuss his latest research in rapid microbiome-based diagnostics of infectious disease and how he sees the microbiome filling a need in point-of-care diagnostics
for infectious disease. He also discusses the epidemic of antibiotic resistance and how this has shaped his research in the critical care space, as well as the biggest challenges he and other scientists face in this field.
NGS in DNA Forensics: Benefits, Challenges, and Future Potential
Cassandra D. Calloway, Ph.D., Assistant Scientist and DNA Program Coordinator, Genetics and Genomics and Forensic Graduate Program, Children’s Hospital Oakland Research Institute and University of California, Davis
Cassandra Calloway of Children’s Hospital Oakland Research Institute and the Universities of California at Davis and San Francisco spoke to CHI to discuss how next generation sequencing, or massively parallel sequencing, is different from
current methods used in DNA forensics. She discusses the benefits of this new technology and its potential for benefitting all forensics labs.
A Multiplexed Approach for Predicting Responses to Cancer Immunotherapy: Implementation and Challenges
Robert A. Anders, M.D., Ph.D., Associate Professor of Pathology, Division of GI and Liver Pathology, Bloomberg-Kimmel Institute for Cancer Immune Therapy, Johns Hopkins Medicine
Robert Anders of Johns Hopkins Medicine speaks to CHI on May 16th, 2017. Dr. Anders will be speaking during the Biomarkers for Cancer Immunotherapy and Combinations meeting at the Next Generation Diagnostics Summit August 15-18th in Washington
Geisinger’s Strategy for Clinical NGS Implementation
Marc S. Williams, M.D., FAAP, FACMG, FACMI, Director, Genomic Medicine Institute, Geisinger Health System
Marc Williams of Geisinger Health System speaks to CHI on May 19th, 2017. Dr. Williams will be speaking during the Clinical NGS Assays: Applications and Interpretation meeting at the Next Generation Diagnostic Summit, August 15th to the 18th in
Precision Medicine Outside of Oncology
Jonathan Pan, Ph.D., MBA, Vice President, Head of Biomarker Strategy and Development, Aevi Genomic Medicine, Inc.
Jonathan Pan of Aevi Genomic Medicine speaks to CHI on May 15th, 2017. Dr. Pan will be speaking during the Companion Diagnostics: Strategy and Partnerships meeting at the Next Generation Diagnostic Summit, August 15th to the 18th in Washington
Implementing Point-of-Care Testing and Pharmacogenetic Testing in the Community Pharmacy
Edana Holliday, PharmD, Clinical Pharmacist, Community Ambulatory Care Services, Rx Clinic Pharmacy; VP, Communications, Pharmacogenetics Center of Excellence
In this podcast from CHI on May 18th, Edana Holliday speaks about how Rx Clinic Pharmacy is working to integrate point-of-care testing and pharmacogenetic testing into their practice, and how use of these methods can bring doctors and pharmacists
into new collaborations. To see her in person, check out the Pharmacy-Based Point-of-Care Testing conference, part of the Next Generation Diagnostics Summit, August 15-18th in Washington DC.
Genome Sequencing Clinical Applications: What Will it Take to Make NGS Standard of Care?
Liz Worthey, Ph.D., Faculty Investigator, Director, Software Development and Informatics, HudsonAlpha Institute for Biotechnology
In this podcast from CHI, on May 11th, 2017 Liz Worthey, Faculty Investigator and Director at HudsonAlpha Institute for Biotechnology sat down to discuss her work in whole genome sequencing to diagnose and monitor rare diseases. She discusses
her team’s work with standardizing NGS tests, utilizing sequencing as a diagnostic test, and challenges to making whole genome sequencing standard of care in clinical practice.
Reimbursement of Companion Diagnostics: Discussions for Precision Medicine
Omar Perez, Ph.D., RAC, Director and Diagnostics Lead, Oncology Programs, Worldwide R&D, Pfizer Inc.
Omar Perez of Pfizer speaks to CHI on May 10, 2017. Dr. March will be speaking during the Companion Diagnostics: Strategy & Partnerships meeting at the Next Generation Diagnostics Summit, August 15-18th in Washington DC.
Walking Down Evidence Street™: Where the Market Meets Evidence
Suzanne Belinson, Ph.D., Executive Director of Clinical Markets, Blue Cross Blue Shield Association
Keynote speaker Suzanne Belinson of Blue Cross Blue Shield Association speaks to CHI on May 9, 2017. Dr. Belinson will be speaking during the Coverage and Reimbursement of Advanced Diagnostics meeting at the Next Generation Diagnostics Summit,
August 15-18th in Washington DC.
2017 Podcast Archive | 2016 Podcast Archive | 2015 Podcast Archive | 2014 Podcast Archive